Cerus Corporation (NASDAQ:CERS) has announced the receipt of a $5 million cash milestone payment from BioOne Corporation. The milestone payment was prompted by Cerus’ recent receipt of CE mark regulatory approval for the INTERCEPT Blood System for plasma in Europe. In addition to the cash payment, Cerus expects to receive an additional milestone payment of BioOne preferred stock worth $5 million in early 2007 pursuant to the terms of its agreement with BioOne. Upon receipt of the cash milestone payment, Cerus forwarded $0.5 million to Baxter Healthcare Corporation in accordance with an agreement relating to the BioOne commercialization rights.

BioOne has commercialization rights for the INTERCEPT Blood System for platelets and plasma in parts of Asia. The agreements between Cerus and BioOne provide for milestone payments to Cerus, as well as royalties based upon sales of the INTERCEPT Blood System for platelets and plasma.

About Cerus Corporation
Cerus Corporation is a biopharmaceutical company that develops and commercializes novel, proprietary products in the fields of blood safety and immunotherapy to provide safer, more effective medical options to patients in areas of substantial unmet medical needs. In the field of immunotherapy, the company is employing its proprietary attenuated Listeria vaccine platform to develop a series of novel therapies to treat cancer, and it is applying its proprietary Killed But Metabolically Active technology platform in research and development of prophylactic and therapeutic vaccines for infectious diseases. In the field of blood safety, the company is developing and commercializing the INTERCEPT Blood System, which is based on the company’s proprietary Helinx technology and is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells. INTERCEPT, INTERCEPT Blood System and Helinx are trademarks of Cerus Corporation.

About Bio-One Corporation
The Company’s principal activity is to design, market and distribute natural, nutritional, and biologically active materials formulated to provide specific health and productivity benefits to human beings and animals. Nutraceuticals are biologically active materials, derived from plant, microbial or animal source. Most of the ingredients included in the Company’s products are vitamins, minerals, herbs and other substances. The Company provides blood analysis test to identify the specific blood composition of individuals and associated nutritional value. On 11-Sep-2003, the Group acquired Physicians Nutraceutical Laboratories and Interactive Nutrition International and Canadian Nutritional Supplement Company in 2004.

Related Health News:

1. BioVeris Corporation Completes Additional Vaccine License for Neisseria meningitidis group Y and Haemophilus influenzae type b BioVeris Corporation (NASDAQ:BIOV) has entered into a new Technology License Agreement with Baxter Healthcare Corporation. BioVeris received an exclusive, worldwide license to certain patent rights...
2. Lux Biosciences Receives Orphan Drug Designation from FDA Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, has announced that the U.S. Food and Drug Administration (FDA)...
3. Golden Hour Technology Innovates Shipment of Platelets and Cord Blood Minnesota Thermal Science, LLC (MTS) has announced general availability of a new shipping container designed to carry platelets and cord blood. Both blood products are...
4. Novartis Pharmaceuticals Corporation Study Says Millions Live with Painful GI Symptoms But Do Not Talk About It While more than 20 million Americans live with the painful and disruptive ABC symptoms – Abdominal pain or discomfort, Bloating and Constipation – many do...
5. SXC Health Solutions receives 2007 Rx Benefit Innovation Award SXC Health Solutions, Inc. (NASDAQ: SXCI; TSX: SXC) ("SXC" or the "Company"), said today that the Pharmacy Benefit Management Institute ("PBMI") has awarded the Company...